Moreover, we first found that RUNX2 can bind to BRG1 and that the knockdown of BRG1 could markedly inhibit the RUNX2-mediated upregulation of the CD44 expression, suggesting that RUNX2 promotes the CD44 expression and EMT depending on the interaction between RUNX2 and BRG1 in CRC cells. Here, SMARCA4 is linked to colorectal carcinoma.